Month: May 2020

NEW YORK and LONDON, May 11, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts on the Company’s stem cell biology-based genomic tool, StemPrintER, for the prediction of disease recurrence in breast cancer patients, will be presented at the American Society of Clinical Oncology’s 2020 Virtual Conference.  All abstracts, including Abstract #1020, which compares Tiziana’s product to current market leader Oncotype DX as part of a poster discussion session, will be available online beginning May 13, 2020 beginning at 5:00 PM ET at abstracts.asco.org.  The American Society of Clinical Oncology (ASCO) Virtual Conference will be held from May 29-31, 2020.In addition,...

Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU careRLF-100, a patented formulation of Aviptadil (synthetic human Vasoactive Intestinal Polypeptide), binds alveolar type 2 cells in the lung. Type 2 cells are essential to oxygen exchange and are selectively targeted by the SARS-CoV-2 virusInhaled VIP may prevent viral destruction of type 2 cells, which could reduce fatal pulmonary complications of COVID-19GENEVA, May 11, 2020 (GLOBE NEWSWIRE) — RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) today announced that its U.S. partner, NeuroRx Inc., has filed an investigational protocol with the U.S. Food and Drug Administration under the Coronavirus Treatment Acceleration Program (CTAP) to conduct a Phase 2/3 clinical...

JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO’s exclusive supplier of COVID-19 antibody testing equipment, to support COVID-19 antibody testing in the UK.hVIVO, based in London, UK, is a world leader in the testing of vaccines and antivirals using human challenge study models.“We are delighted to exclusively partner with Quotient to bring fast and accurate COVID-19 antibody testing to the UK. Open Orphan plc, via...

For immediate release            11 May 2020Serabi Gold plc(“Serabi” or the “Company”)Continuing Sao Chico mine-site exploration successRegional Exploration shows excellent promiseSerabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to announce further drilling results at the Sao Chico extension drilling programme and results of the regional geochemical sampling programs on the Palito Complex exploration tenement.A PDF version of this news release is available using the following link – https://bit.ly/2xMSyTMHighlightsResults for a further eight surface holes and ten underground holes at Sao Chico since the previous exploration news release of 3 March 2020. The new surface drill hole results included significant intersections of:5.30m @ 12.10g/t Au (Hole: 20-SC-166)3.40m @ 3.94g/t...

STOCKHOLM, SWEDEN – May 11, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has received full and nationwide cost reimbursement for its implant product OssDsign Cranial PSI in Japan. The decision was made by the Ministry of Health, Labor and Welfare of Japan (MHLW), and will come into force in early June 2020.   OssDsign is an innovative company that designs and manufactures implants and material technology for bone regeneration. The granting of national cost reimbursement for OssDsign Cranial PSI represents an important milestone in its establishment in Japan. OssDsign has already obtained good relationships with key institutions, policy makers and reference clinics and is now conducting final negotiations with a local business partner to gain access to a national distribution...

STOCKHOLM, SVERIGE 11 maj 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign har erhållit fullständig och nationell kostnadsersättning för sin implantatprodukt OssDsign Cranial PSI i Japan. Beslutet har fattats av Ministry of Health, Labour and Welfare of Japan (MHLW), och kommer att träda i kraft i början av juni 2020.  OssDsign är ett innovativt bolag som designar och tillverkar implantat och materialteknik för reparation av benvävnad. Godkännandet av nationell kostnadsersättning för OssDsign Cranial PSI utgör en viktig milstolpe i bolagets etablering i Japan. OssDsign har redan etablerat goda relationer med viktiga institutioner, beslutsfattare och referenskliniker och genomför nu slutförhandlingar med en lokal affärspartner för att få tillgång till ett nationellt distributionsnätverk.”Att...

IQE plcCardiff, UK11 May 2020Director/PDMR ShareholdingIQE plc (AIM:  IQE, “IQE” or the “Group”), the leading manufacturer of advanced semiconductor wafer products for the global semiconductor industry, was notified on 7 May 2020 that Dr Drew Nelson, Chief Executive Officer of the Company, has delivered a further 1,121,711 ordinary shares of 1 pence each in the Company (“Ordinary Shares”) to Equities First Holdings (“EFH”), having received a margin call under the terms of his sale and repurchase agreement with EFH, first announced on 06 August 2019 (“the Agreement”). The total number of Ordinary Shares subject to the Sale and Repurchase Agreement is now 12,121,711 Ordinary Shares (“EFH Sale Shares”).Under the terms of the Agreement, Dr Nelson is obligated to repurchase (and EFH is obligated to sell to Dr Nelson)...

The Annual General Meeting of Shareholders of Panevezio statybos trestas AB took place on 29 April 2020 at 10:00 am. and decided to allocate EUR 0.03 dividend per share. Panevezio statybos trestas AB  will close the list of shareholders for dividend payment on 14 May 2020 at the end of the working day of the settlement system. Proceeding from the above, the ex-date is 13 May 2020. From that date the new owner of the shares of Panevezio statybos trestas AB (trading code PTR1L, ISIN code LT0000101446), which have been acquired on stock exchange with settlement cycle of T+2, is not entitled to dividends for the year 2019.Dalius GeseviciusManaging DirectorPhone: (+370 45) 505 503